Business Description
Shukra Pharmaceuticals Ltd
ISIN : INE551C01044
Total Employee Number:
115Description
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.19 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.15 | |||||
Interest Coverage | 23.14 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 41.47 | |||||
Beneish M-Score | -1.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.9 | |||||
3-Year EBITDA Growth Rate | 55.2 | |||||
3-Year EPS without NRI Growth Rate | 59.6 | |||||
3-Year FCF Growth Rate | -86.7 | |||||
3-Year Book Growth Rate | -16.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.63 | |||||
Quick Ratio | 3.03 | |||||
Cash Ratio | 0.26 | |||||
Days Inventory | 305.16 | |||||
Days Sales Outstanding | 77.01 | |||||
Days Payable | 211.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 49.4 | |||||
3-Year Average Share Buyback Ratio | -82.5 | |||||
Shareholder Yield % | -0.33 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.06 | |||||
Operating Margin % | 44.59 | |||||
Net Margin % | 38.88 | |||||
EBITDA Margin % | 58.74 | |||||
FCF Margin % | -15.76 | |||||
OCF Margin % | 5.25 | |||||
ROE % | 30.28 | |||||
ROA % | 22.7 | |||||
ROIC % | 25.17 | |||||
3-Year ROIIC % | 24.47 | |||||
ROC (Joel Greenblatt) % | 52.4 | |||||
ROCE % | 38.37 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 83.02 | |||||
PE Ratio without NRI | 83.02 | |||||
Shiller PE Ratio | 98.41 | |||||
PEG Ratio | 1.2 | |||||
PS Ratio | 32.46 | |||||
PB Ratio | 20.23 | |||||
Price-to-Tangible-Book | 20.21 | |||||
Price-to-Operating-Cash-Flow | 466.4 | |||||
EV-to-EBIT | 60.8 | |||||
EV-to-EBITDA | 54.52 | |||||
EV-to-Revenue | 32.02 | |||||
EV-to-FCF | -153.97 | |||||
Price-to-GF-Value | 4.84 | |||||
Price-to-Projected-FCF | 38.73 | |||||
Price-to-Median-PS-Value | 21.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.32 | |||||
| Price-to-Net-Current-Asset-Value | 32.38 | |||||
Earnings Yield (Greenblatt) % | 1.64 | |||||
FCF Yield % | -0.65 | |||||
Forward Rate of Return (Yacktman) % | 19.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shukra Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 748.586 | ||
| EPS (TTM) (₹) | 0.78 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (₹) | - | ||
| 20-Day SMA (₹) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (₹) | 40.06 - 44.39 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shukra Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shukra Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shukra Pharmaceuticals Ltd Frequently Asked Questions
What is Shukra Pharmaceuticals Ltd(NSE:SHUKRAPHAR)'s stock price today?
The current price of NSE:SHUKRAPHAR is ₹41.44. The 52 week high of NSE:SHUKRAPHAR is ₹44.39 and 52 week low is ₹40.06.
When is next earnings date of Shukra Pharmaceuticals Ltd(NSE:SHUKRAPHAR)?
The next earnings date of Shukra Pharmaceuticals Ltd(NSE:SHUKRAPHAR) is .
Does Shukra Pharmaceuticals Ltd(NSE:SHUKRAPHAR) pay dividends? If so, how much?
Shukra Pharmaceuticals Ltd(NSE:SHUKRAPHAR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Shukra Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers